UGN-103 shows promising 77.8% efficacy in treating recurrent low-grade bladder cancer, paving the way for a potential FDA approval.
Andrea Eleazar, MHS
Andrea Eleazar, MHS, is an assistant editor for Targeted Oncology, with interests in noncommunicable diseases, health equity research, and global health. Eleazar holds a Master of Health Science in Epidemiology from the Johns Hopkins Bloomberg School of Public Health, as well as a BS in Public Health and certificate in Writing & Publishing from Drexel University.
Articles by Andrea Eleazar, MHS
The FDA designates M2T-CD33 as an orphan drug, highlighting its potential as a safer, innovative treatment for acute myeloid leukemia.
The EDGE-Gastric trial reveals promising results for domvanalimab and zimberelimab in treating advanced gastric cancer, showcasing durable efficacy and manageable safety.
A novel combination therapy shows promise for preserving kidneys in high-risk upper tract urothelial carcinoma, challenging traditional treatment methods.
New data reveals lifileucel shows promising efficacy and safety in treating advanced non-small cell lung cancer, paving the way for potential FDA approval.
Vorasidenib shows significant long-term benefits for IDH-mutant glioma patients, enhancing survival and delaying treatment needs post-surgery.
Whole-genome sequencing uncovers critical genomic insights in salivary gland cancer, paving the way for targeted therapies and improved patient outcomes.
A recent study highlights disparities in cancer clinical trials among low- and middle-income countries, emphasizing the need for enhanced research initiatives.
New response criteria for acute GVHD enhance prediction of nonrelapse mortality, potentially transforming clinical trial designs and treatment evaluations.
VS-7375 shows promising safety and antitumor activity in advanced solid tumors with KRAS G12D mutation, paving the way for further clinical evaluation.
A new trial shows that the combination of belzutifan and lenvatinib improves progression-free survival in advanced renal cell carcinoma patients.
FDA designates ZEN-3694 as an orphan drug, offering hope for patients with NUT carcinoma with no current approved therapies.
A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.
A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.
The FDA designates daraxonrasib as an orphan drug for pancreatic cancer, targeting RAS mutations with promising trial results.
The FDA fast-tracks JSKN003, a promising treatment for platinum-resistant ovarian cancer, enhancing development and approval processes for this critical therapy.
GLP-1 receptor agonists show promise in treating various chronic conditions, but potential risks and unanswered questions remain for care of patients with NETs.
Recent findings from the MIRASOL trial reveal significant advancements in treatment options for platinum-resistant ovarian cancer, emphasizing effective therapy sequencing.
A study reveals that obesity and sex significantly influence liver recurrence and survival rates in pancreatic cancer patients post-surgery.
New research highlights narsoplimab's potential to significantly reduce mortality in high-risk patients with thrombotic microangiopathy after stem cell transplants.
Results of a recent study reveal significant racial differences in renal cell carcinoma histology and outcomes, highlighting the need for ancestry-informed kidney care strategies.
Revumenib gains FDA approval for treating relapsed mNPM1 AML, showcasing promising efficacy and safety data from the AUGMENT-101 trial.
The FDA fast tracks MT-125, a promising new treatment for glioblastoma, enhancing patient care and expediting drug development.
New research reveals that sustained MRD negativity after ASCT allows safe discontinuation of lenalidomide maintenance in multiple myeloma patients.
The FDA fast-tracks pamlectabart tismanitin, a promising treatment for relapsed multiple myeloma, enhancing its development and review process.
New findings reveal that adding sapanisertib to weekly paclitaxel significantly improves progression-free survival in advanced ovarian cancer patients.
Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.
FDA prioritizes review of enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, showing promising results in reducing recurrence and mortality.
The FDA reviews XS003, a new nilotinib formulation for CML, promising improved safety and convenience for patients.
A groundbreaking study reveals the effectiveness of dabrafenib and trametinib in treating advanced thyroid cancer, showcasing significant survival benefits.